TWISTed HIF: Revisiting Smooth Muscle HIF-1α Signaling in Pulmonary Hypertension
Yuanjun Shen,Elena A. Goncharova
DOI: https://doi.org/10.1152/ajplung.00285.2018
2018-01-01
Abstract:Editorial FocusTWISTed HIF: revisiting smooth muscle HIF-1α signaling in pulmonary hypertensionYuanjun (Steven) Shen and Elena A. GoncharovaYuanjun (Steven) ShenPittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania and Elena A. GoncharovaPittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PennsylvaniaDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PennsylvaniaDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PennsylvaniaPublished Online:04 Sep 2018https://doi.org/10.1152/ajplung.00285.2018This is the final version - click for previous versionMoreSectionsPDF (234 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat The transcription factor hypoxia-inducible factor-1 (HIF-1) is a master regulator of oxygen homeostasis that acts as a heterodimeric complex composed of oxygen-sensitive α-subunit and oxygen-insensitive β-subunit. In oxygenized cells, HIF-1α is inactivated via hydroxylation by prolyl hydroxylase domain proteins and factor inhibiting HIF, leading to HIF-1α ubiquitination and proteasomal degradation. Hypoxia results in stabilization and nuclear translocation of HIF-1α, where activated HIF-1 initiates adaptive response to hypoxia by inducing or repressing broad range of genes involved in regulation of vascular tone, cellular metabolism, proliferation, survival, and autophagic response (4, 12). In lung, HIF-1 orchestrates physiological response to hypoxia and contributes to the pathogenesis of numerous disorders, including lung cancer, acute lung injury, pulmonary fibrosis, and pulmonary hypertension (PH) (12, 14).PH, a progressive disease with multifactorial origin and poor prognosis, manifests by vasoconstriction and remodeling of small pulmonary arteries (PAs), leading to elevated PA pressure, increased right ventricle afterload, and heart failure. Chronic hypoxia is a major trigger of World Health Organization group III PH and is likely playing a role in the pathogenesis of other groups, including pulmonary arterial hypertension (PAH) (12, 14). Prolonged hypoxia promotes vasoconstriction and pulmonary vascular remodeling, and has been routinely used to model PH in mice, rats and calves. Not surprisingly, the role of HIF-1 in PH had been extensively studied. HIF-1α is overexpressed in plexiform lesions and isolated endothelial cells (ECs) from patients with severe PH (3, 14), where it controls expression of promitogenic factors and supports increased cell proliferation and survival. Further supporting the pathogenic role of endothelial HIF-1 in PH, endothelial HIF-1/2α deficiency in mice protects against pulmonary fibrosis-associated PH (5). In contrast to ECs, the role of HIF-1α in PA vascular smooth muscle (VSM) cells (PAVSMCs), critical players in both sustained vasoconstriction and remodeling, remains controversial. Intriguingly, both increased and reduced protein levels of HIF-1α had been reported in human PAH PAVSMCs (1, 3, 13), and VSM-specific HIF-1α knockout in mice either protected from (2) or worsened hypoxia-induced PH (8).In this issue of the American Journal of Physiology-Lung Cellular and Molecular Physiology, Wang and colleagues (15) present very interesting findings that may, at least in part, shed a light on the dual role of HIF-1α in PH PAVSMCs (15). Using gain- and loss-of-function approach, the authors show that not only overexpression but also depletion of HIF-1α in human PAVSMCs results in increased production and secretion of endothelin 1 (ET-1). Further confirmed in mouse HIF-1α-deficient PAVSMCs, this observation supports previous studies from the authors’ group showing that HIF-1α is instrumental in the maintenance of low pulmonary vascular tone and that SMC-specific HIF-1α loss in mice promotes vasoconstriction-induced PH, but not pulmonary vascular remodeling (3, 8). Further exploring the mechanism, the authors identified microRNA-543 as a reciprocal effector of HIF-1α and provided mechanistic link from HIF-1α deficiency via upregulation of microRNA-543 and consequent suppression of Twist family BHLH transcription factor (TWIST) to increased ET-1 expression. These findings add one more piece of the information to the HIF-1α puzzle and provide additional mechanistic background to the function of HIF-1α as a regulator of vascular tone in PH.There are, however, several important questions that call for further investigation. ET-1, a potent vasoconstrictor and well-known driver of PH pathogenesis, is highly expressed by PA endothelial cells (ECs), and production is further increased in PAH (7). Whether PAVSMC-derived ET-1 adds significantly to EC-produced ET-1 pool is not clear, and the relationship between PAVSMCs and ECs in regulating ET-1 secretion remains to be established. Furthermore, ET-1 stabilizes HIF-1α through inhibition of prolyl hydroxylase domain proteins (6), and more studies are needed to determine why this mechanism is dysfunctional in human PAH PAVSMCs.HIF-1 cross talks with multiple signaling pathways and can be activated without hypoxic exposure via various mechanisms, including increased H2O2 due to downregulation of superoxide dismutase 2, elevated growth factors/receptor tyrosine kinases, activation of pro-proliferative/prosurvival Akt, mechanistic target of rapamycin (mTOR), and extracellular signal-regulated kinase or loss of growth suppressors, such as p53, phosphatase and tensin homolog (PTEN), and Hippo (4), all of which are involved in PAH PAVSMC pathology (10, 11). In cancer, normoxic HIF-1 activation supports a shift to the aerobic glycolysis and further activates mTOR, providing proliferative and survival advantage (1). PAVSMCs in human PAH acquire proliferative, apoptosis-resistant phenotype, characterized by glycolytic metabolic shift, and normoxic HIF-1α activation had been reported in and strongly linked with PAVSMC metabolic and signaling reprograming, pulmonary vascular remodeling, and overall PH (1, 11, 12, 14) (Fig. 1A).Fig. 1.Potential mechanisms of hypoxia-inducible factor-1 (HIF-1α) upregulation (A) or deficiency (B) in pulmonary arterial vascular smooth muscle cells (PAVSMCs) in pulmonary hypertension. A: chronic hypoxia, growth factors, metabolic, and signaling abnormalities, such as increased H2O2 production due to downregulation of SOD2, constitutive activation of proproliferative Akt, extracellular-regulated kinase (ERK), and mechanistic target of rapamycin (mTOR), and loss of function of growth suppressors, such as phosphatase and tensin homolog (PTEN) and Hippo, lead to activation of HIF-1α. HIF-1α, in turn, promotes increased endothelin 1 (ET-1) production and PAVSMC vasoconstriction and supports glycolytic metabolic shift, increased PAVSMC proliferation, survival, and pulmonary vascular remodeling. B: Wang and colleagues (15) report that deficiency of HIF-1α in pulmonary hypertension (PH) PAVSMC increases of microRNA543, which further supports HIF-1α deficiency and downregulates Twist family BHLH transcription factor (TWIST). This, in turn, induces increased expression and secretion of ET-1 and PAVSMC vasoconstriction. The role of HIF-1α deficiency in PAVSMC remodeling remains to be determined. PDK, phosphoinositide-dependent protein kinase; PDH, pyruvate dehydrogenase.Download figureDownload PowerPointAlthough this study provides insight into the mechanism(s) by which HIF-1α deficiency may induce sustained PAVSMC vasoconstriction (15), an important question about the status of HIF-1α in PAH PAVSMC remodeling remains to be answered. Given that both PAVSMC-specific increase and deficiency of HIF-1α had been reported in patients with PAH (1, 3, 13, 15), PAVSMC-focused multipatient proteomic studies are needed to clarify the status of HIF-1α in this disease. Available findings allow us to speculate that there may be at least two distinct PAH subphenotypes, characterized by either increased or reduced PAVSMC HIF-1α, but nevertheless sharing similar pathological increase in ET-1 production and vasoconstrictive response. Whether HIF-1α deficiency attenuates or supports proliferative/apoptosis-resistant PAVSMC phenotype in PAH, however, remains to be determined. ET-1 has moderate mitogenic effects on PAVSMCs and fibroblasts; promotes extracellular matrix production; and impacts, although moderately, in pulmonary vascular remodeling (7). It acts as an inhibitor of antiproliferative O2-sensitive K+ channel (Kv1.5), decreased expression of which is reported in both HIF-1α-overexpressing and HIF-1α-deficient PAVSMCs (1, 3), supporting pathological role of HIF-1α loss in PAVSMC remodeling. On the other hand, TWIST, a direct and indirect downstream effector of HIF-1α, is emerging pro-oncogene and promotes PH via stimulating endothelial-to-mesenchymal transition (9), and miR-543, while never been linked to PH, shows either pro- or antiproliferative properties depending on cell type (Fig. 1B).In conclusion, this article opens several interesting avenues for further investigation. Although proposing miR-543 as a potential molecular target to reduce ET-1 production in PH, further studies will be needed to clarify the status of HIF-1α in patients with PAH and dissect the role of the HIF-1α/miR-543/TWIST/ET-1 axis in pulmonary vascular remodeling.GRANTSThis work is supported in part by National Heart, Lung, and Blood Institute Grants HL-113178 and HL-130261 (to E. A. Goncharova).DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSY.S.S. and E.A.G. prepared figure; Y.S.S. and E.A.G. edited and revised manuscript; E.A.G. drafted manuscript; E.A.G. approved final version of manuscript.REFERENCES1. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 294: H570–H578, 2008. doi:10.1152/ajpheart.01324.2007. Link | ISI | Google Scholar2. Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, Beussink L, Dettman RW, Berkelhamer SK, Steinhorn RH, Shah SJ, Schumacker PT. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med 189: 314–324, 2014. doi:10.1164/rccm.201302-0302OC. Crossref | PubMed | ISI | Google Scholar3. Barnes EA, Chen CH, Sedan O, Cornfield DN. Loss of smooth muscle cell hypoxia inducible factor-1α underlies increased vascular contractility in pulmonary hypertension. FASEB J 31: 650–662, 2017. doi:10.1096/fj.201600557R. Crossref | PubMed | ISI | Google Scholar4. Brahimi-Horn MC, Pouysségur J. HIF at a glance. J Cell Sci 122: 1055–1057, 2009. doi:10.1242/jcs.035022. Crossref | PubMed | ISI | Google Scholar5. Bryant AJ, Carrick RP, McConaha ME, Jones BR, Shay SD, Moore CS, Blackwell TR, Gladson S, Penner NL, Burman A, Tanjore H, Hemnes AR, Karwandyar AK, Polosukhin VV, Talati MA, Dong HJ, Gleaves LA, Carrier EJ, Gaskill C, Scott EW, Majka SM, Fessel JP, Haase VH, West JD, Blackwell TS, Lawson WE. Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 310: L249–L262, 2016. doi:10.1152/ajplung.00258.2015. Link | ISI | Google Scholar6. Caprara V, Scappa S, Garrafa E, Di Castro V, Rosanò L, Bagnato A, Spinella F. Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. Life Sci 118: 185–190, 2014. doi:10.1016/j.lfs.2014.02.030. Crossref | PubMed | ISI | Google Scholar7. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract 2014: 62–78, 2014. doi:10.5339/gcsp.2014.29. Crossref | PubMed | Google Scholar8. Kim YM, Barnes EA, Alvira CM, Ying L, Reddy S, Cornfield DN. Hypoxia-inducible factor-1α in pulmonary artery smooth muscle cells lowers vascular tone by decreasing myosin light chain phosphorylation. Circ Res 112: 1230–1233, 2013. doi:10.1161/CIRCRESAHA.112.300646. Crossref | PubMed | ISI | Google Scholar9. Mammoto T, Muyleart M, Konduri GG, Mammoto A. Twist1 in Hypoxia-induced Pulmonary Hypertension through Transforming Growth Factor-β-Smad Signaling. Am J Respir Cell Mol Biol 58: 194–207, 2018. doi:10.1165/rcmb.2016-0323OC. Crossref | PubMed | ISI | Google Scholar10. Pullamsetti SS, Savai R, Seeger W, Goncharova EA. Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. Am J Respir Crit Care Med 195: 425–437, 2017. doi:10.1164/rccm.201606-1226PP. Crossref | PubMed | ISI | Google Scholar11. Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation 131: 1691–1702, 2015. doi:10.1161/CIRCULATIONAHA.114.006979. Crossref | PubMed | ISI | Google Scholar12. Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 183: 152–156, 2011. doi:10.1164/rccm.201009-1393PP. Crossref | PubMed | ISI | Google Scholar13. Tang H, Babicheva A, McDermott KM, Gu Y, Ayon RJ, Song S, Wang Z, Gupta A, Zhou T, Sun X, Dash S, Wang Z, Balistrieri A, Zheng Q, Cordery AG, Desai AA, Rischard F, Khalpey Z, Wang J, Black SM, Garcia JGN, Makino A, Yuan JX. Endothelial HIF-2α contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 314: L256–L275, 2018. doi:10.1152/ajplung.00096.2017. Link | ISI | Google Scholar14. Veith C, Schermuly RT, Brandes RP, Weissmann N. Molecular mechanisms of hypoxia-inducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension. J Physiol 594: 1167–1177, 2016. doi:10.1113/JP270689. Crossref | PubMed | ISI | Google Scholar15. Wang CC, Ying L, Barnes EA, Adams ES, Kim FY, Engel KW, Alvira CM, Cornfield DN. Pulmonary artery smooth muscle cell HIF-1α regulates endothelin expression via microRNA-543. Am J Physiol Lung Cell Mol Physiol 315: TBA, 2018. doi:10.1152/ajplung.00475.2017. Link | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: E. A Goncharova, BST E1259, 200 Lothrop St., Pittsburgh, PA 15261 (e-mail: [email protected]edu). Download PDF Back to Top Next FiguresReferencesRelatedInformation Related ArticlesPulmonary artery smooth muscle cell HIF-1α regulates endothelin expression via microRNA-543 04 Sep 2018American Journal of Physiology-Lung Cellular and Molecular Physiology Press Release E-cigarette Use during Pregnancy Creates Lung Dysfunction in Babies - December 8, 2022 More from this issue > Volume 315Issue 3September 2018Pages L387-L389 Copyright & PermissionsCopyright © 2018 the American Physiological Societyhttps://doi.org/10.1152/ajplung.00285.2018PubMed29975104History Received 18 June 2018 Accepted 4 July 2018 Published online 4 September 2018 Published in print 1 September 2018 Metrics